MedCity News reports that AstraZeneca has signed a 5-year agreement with PatientsLikeMe, a patient-powered research network.
Ed Godber, executive vice president of Life Sciences Ventures at PatientsLikeMe, said unlike most of its pharma collaborations, which have been with US affiliates of drug companies, “this one integrates us into the engine of R&D globally. AstraZeneca is putting the patient voice and PatientsLikeMe into the DNA of their innovation process.”
The pharmaceutical company will initially focus on respiratory diseases, as well as lupus, oncology and diabetes. It will rely on data from PatientsLikeMe to influence the course of drug development.
